APTOCROM Inc. Stock

A109960

KR7109960005

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 05/08/2026			5-day change	1st Jan Change
1,664.00 ^KRW	+0.85%		+4.33%	-66.72%

07-01	Aprogen Biologics Inc. announced that it has received KRW 50.8 billion in funding from APTOCROM Inc.	CI
05-26	Aprogen Biologics Inc. announced that it expects to receive KRW 50.8 billion in funding from APTOCROM Inc.	CI

Aptocrom Inc, formerly AP Healthcare Inc, is a Korea-based company primarily engaged in the pharmaceutical business. The Company operates its business through three segments. The Pharmaceutical Business segment is mainly engaged in the distribution and sale of drugs such as digestive organs medicine, outer skin medicine, nutrient tonic alteration and antibiotics. The Insulation Business segment is mainly engaged in the production, design, manufacturing and construction of industrial insulation. The Rental Business segment is mainly engaged in the real estate business such as offices and laboratories. The Company sells its products in domestic and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
05/08/26	₩1,664.00	+0.85%	3,722
04/08/26	₩1,650.00	-0.06%	22,958
03/08/26	₩1,651.00	-0.90%	2,267
31/07/26	₩1,666.00	+4.32%	3,923
30/07/26	₩1,597.00	+0.13%	3,909

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Stock Market
Stocks
A109960 Stock

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	18.37B 12.91M 11.18M 10.42M 9.58M 18.09M 1.23B 18.3M 122M 48.06M 614M 48.48M 47.41M 2.03B	P/E 2024	-2.12x	P/E 2025	-9.5x
Enterprise Value	1.17B 825K 715K 666K 613K 1.16M 78.48M 1.17M 7.83M 3.07M 39.27M 3.1M 3.03M 130M	EV / Sales 2024	4.85x	EV / Sales 2025	3.87x
Free-Float	41.27%	Yield 2024 *	-	Yield 2025	-

07-01	Aprogen Biologics Inc. announced that it has received KRW 50.8 billion in funding from APTOCROM Inc.	CI
05-26	Aprogen Biologics Inc. announced that it expects to receive KRW 50.8 billion in funding from APTOCROM Inc.	CI
05-14	APTOCROM Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-08	Aprogen Medicines Inc. announced that it has received KRW 12 billion in funding from APTOCROM Inc.	CI
05-07	APTOCROM Inc. announced that it has received KRW 12.00000164 billion in funding from Nexkonics Inc.	CI
04-28	Aprogen Medicines Inc. announced that it expects to receive KRW 12 billion in funding from APTOCROM Inc.	CI
04-28	APTOCROM Inc. announced that it expects to receive KRW 12.00000164 billion in funding from Nexkonics Inc.	CI
03-20	APTOCROM Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-16	APTOCROM Inc. announces Annual dividend	CI
11-13	APTOCROM Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
13/08/25	APTOCROM Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25/06/25	AP Healthcare Inc. announced that it has received KRW 10 billion in funding from Aprogen, Inc.	CI
22/05/25	Aprogen Medicines Inc. agreed to acquire an additional 20.06% stake in AP Healthcare Inc. from Aprogen Biologics Inc. for KRW 58.4 billion.	CI

1 day	+0.85%
1 week	+4.33%
Current month	-0.12%
1 month	-2.92%
3 months	-45.62%
6 months	-65.90%
Current year	-66.72%

1 week	1,547	1,694
1 month	1,430	1,770
Current year	1,430	5,400
1 year	1,430	11,820
3 years	1,430	49,900
5 years	1,430	113,000
10 years	1,430	426,000

Manager	Title	Age	Since
Jung-Chool Kim CEO	Chief Executive Officer	70	23/03/2022
Young-Suk Yeom AUD	Comptroller/Controller/Auditor	51	-
Jong-Su Kang SAM	Sales & Marketing	62	-

APTOCROM Inc. Stock

Stocks

A109960

KR7109960005

Pharmaceuticals

Valuation: APTOCROM Inc.

Chart: APTOCROM Inc.

Latest news : APTOCROM Inc.

Quotes and Performance

Course Extremes

Managers and Directors: APTOCROM Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Director	Title	Age	Since
Soon-Kyu Park BRD	Director/Board Member	59	-
Jung-Chool Kim BRD	Director/Board Member	70	23/03/2022
Jae-Seob Kim BRD	Director/Board Member	63	10/01/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
APTOCROM INC.	+0.85%	+4.33%	-73.84%	-93.94%	12.91M
ELI LILLY AND COMPANY	+4.86%	-3.32%	+52.73%	+160.26%	1,043B
JOHNSON & JOHNSON	+1.04%	-2.99%	+50.87%	+52.38%	621B
ABBVIE INC.	+0.98%	-6.49%	+24.00%	+66.66%	435B
ROCHE HOLDING AG	+0.55%	+4.19%	+48.11%	+39.02%	361B
NOVARTIS AG	+0.92%	-0.69%	+36.30%	+40.12%	293B
ASTRAZENECA PLC	+0.32%	-5.04%	+9.27%	+10.95%	251B
AMGEN INC.	+4.57%	+5.21%	+35.91%	+67.64%	220B
NOVO NORDISK A/S	+0.55%	-10.14%	+2.71%	-45.51%	201B
GILEAD SCIENCES, INC.	-2.58%	-0.73%	+17.16%	+67.46%	164B
Average	+0.78%	-3.01%	+20.32%	+36.51%	358.92B
Weighted average by Cap.	+0.83%	-3.79%	+38.62%	+76.36%

	2024	2025
Net sales	16.4B 11.52M 9.98M 9.3M 8.56M 16.16M 1.1B 16.34M 109M 42.91M 548M 43.28M 42.33M 1.82B	9.81B 6.89M 5.97M 5.56M 5.12M 9.66M 655M 9.77M 65.39M 25.66M 328M 25.88M 25.31M 1.09B
Net income	-28.09B -19.74M -17.1M -15.94M -14.66M -27.68M -1.88B -27.98M -187M -73.51M -939M -74.15M -72.51M -3.11B	-5.56B -3.91M -3.38M -3.15M -2.9M -5.48M -371M -5.54M -37.07M -14.55M -186M -14.67M -14.35M -616M
Net Debt	-25.07B -17.62M -15.26M -14.22M -13.08M -24.69M -1.67B -24.97M -167M -65.59M -838M -66.16M -64.7M -2.78B	-17.19B -12.08M -10.46M -9.75M -8.97M -16.94M -1.15B -17.13M -115M -44.99M -575M -45.38M -44.38M -1.9B